Cellis
Company Details
Status: Private
Employees: 11-50
Location:
Warsaw, Poland
Type:
sample
Technology:
sample
sample
About: At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors.
We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth.
Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Cellis | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.